CXCR4 and neoplasm: Thus, future immune-based strategies may be focused on combinations of different immune checkpoint inhibitors with substances targeting CXCL12/CXCR4 and reversal of local immunosuppression in the microenvironment, converting a ‘cold’ tumor into a ‘hot’ tumor [25,70].